ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2527

Prozone Phenomenon Leads to Low IgG4 Concentrations in IgG4-Related Disease

Arezou Khosroshahi1, Lynn A. Cheryk2, Mollie Carruthers1, Judith A. Edwards2, Donald B. Bloch3 and John H. Stone1, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Mayo Medical Laboratories, Mayo Medical Laboratories, Andover, 3Rheumatology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Immunoglobulin (IG) and laboratory tests

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

IgG4-related disease (IgG4-RD) is frequently associated with elevations in serum IgG4 concentration. However, the frequency of serum IgG4 elevation varies in published series from 44%-100%. The prozone effect, also known as the “hook” effect, occurs when antigen excess interferes with antibody-based assay methods that require immune complex formation for detection, and can lead to spuriously low results. Additional sample dilutions are the solution to the prozone effect.  After identifying the prozone effect in one patient with IgG4-RD whose serum IgG4 corrected following appropriate dilutions from 17 to 1850 mg/dL (nl: 2.4–121 mg/dL), we examined additional samples to determine the frequency of this problem.

Methods:

We re-tested 38 serum samples from patients with the diagnosis of IgG4-RD whose original serum IgG4 results had been reported earlier. The IgG subclasses were measured by nephelometry in dilutions up to 1:160,000, using two different commercially-available reagents (Siemens; The Binding Site).  The testing laboratory was blinded to the patients’ clinical history and previous values. The serum IgG4 concentrations from these assays were compared to the original results.

Results:

Falsely low IgG4 values were reported in 10/38 patients (26%) using The Binding Site assay   (Table). The prozone effect was identified as the cause of 8 incorrect values (21% of all samples tested). Correction of the prozone effect by sample dilution until the concentration reported was stable, led to a revision of the mean IgG4 result from 21.6 to 2440. In contrast, samples measured by the Siemens reagent were checked automatically for antigen excess as part of the testing method; the appropriate numbers of dilutions were performed either automatically by the instrument or manually as the result of a flag associated with the value, thereby avoiding the prozone effect.  The Binding Site assay gave no indication that antigen excess might be present.

All 8 patients whose samples were affected by the prozone effect had active IgG4-RD, and 6 had multi-organ disease. Medical record review indicated that the original clinical decision regarding further evaluation (e.g., tissue biopsy) or treatment might have been different had the correct value been known to the clinician. 

Conclusion:

We have identified a major issue in the serological measurement of IgG4 concentrations. The prozone effect which led to substantial underestimations of IgG4 concentrations in 21% of the samples, offers potential explanations for the poor correlation observed between disease activity and serum IgG4 level in some patients.  This phenomenon should be considered when the serum IgG4 measurement appears discordant with the clinician’s assessment of disease activity.

Table. Characteristics of patients with IgG4-RD with significant differences in their retested IgG4 results

 

Case #

* Original reported IgG4 values  (mg/dL)

** Retested IgG4 values (mg/dL)

X-fold increase after dilution

Number of affected organs

Active disease

Presence of prozone effect

1

10.3

2470

247

1

Yes

Yes

2

28.4

941

33

3

Yes

Yes

3

29.3

219

7.5

1

Yes

No

4

59.8

337

5.6

1

Yes

No

5

12.7

5340

420

3

Yes

Yes

6

17.6

1850

105

4

Yes

Yes

7

8.0

5160

645

7

Yes

Yes

8

43.9

1030

23

4

Yes

Yes

9

14.4

1910

132

7

Yes

Yes

10

37.5

819

22

1

Yes

Yes

*   The Binding Site reagent was used for the assay

** Siemens reagent was used for the assay


Disclosure:

A. Khosroshahi,
None;

L. A. Cheryk,
None;

M. Carruthers,
None;

J. A. Edwards,
None;

D. B. Bloch,
None;

J. H. Stone,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prozone-phenomenon-leads-to-low-igg4-concentrations-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology